ACRX Insider Trading Activity and SEC Form 4 Filings
ACRX insider trading summary
No open-market insider purchases or sales of Acelrx Pharmaceuticals Inc (ACRX) have been reported on SEC Form 4 in the past 12 months.
Latest ACRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 13, 2023 | Vincent J. Angotti | Chief Executive Officer | Buy | $7K (10,000 @ $0.73) |
| Sep 11, 2023 | Vincent J. Angotti | Chief Executive Officer | Buy | $8K (10,000 @ $0.80) |
| Aug 25, 2023 | Pamela P Palmer | Chief Medical Officer | Sell | $8K (7,442 @ $1.09) |
| Aug 24, 2023 | Pamela P Palmer | Chief Medical Officer | Sell | $11K (9,514 @ $1.17) |
| Jun 7, 2022 | Vincent J. Angotti | Chief Executive Officer | Buy | $10K (46,400 @ $0.22) |
| Jun 15, 2020 | Vincent J. Angotti | Chief Executive Officer | Buy | $10K (7,547 @ $1.33) |
| Jun 15, 2020 | Adrian Adams | Director | Buy | $129K (100,000 @ $1.29) |
| Nov 12, 2019 | Mark G Edwards | Director | Buy | $45K (25,000 @ $1.78) |
| Nov 11, 2019 | Vincent J. Angotti | Chief Executive Officer | Buy | $15K (8,379 @ $1.79) |
| Aug 26, 2019 | Mark G Edwards | Director | Buy | $11K (5,000 @ $2.17) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.